Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Phase 2, Placebo Controlled, 2 Arm Study To Evaluate Dupilumab In Patients With Bilateral Nasal Polyposis And Chronic Symptoms Of Sinusitis

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Phase 2, Placebo Controlled, 2 Arm Study To Evaluate Dupilumab In Patients With Bilateral Nasal Polyposis And Chronic Symptoms Of Sinusitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dupilumab (Primary) ; Mometasone
  • Indications Nasal polyps; Rhinosinusitis
  • Focus Therapeutic Use
  • Sponsors Sanofi

    • Most Recent Events

    • 25 Apr 2022 Data from three phase 3 studies (NCT01920893, NCT02912468 and NCT02898454) were used to validate chronic rhinosinusitis health-related quality-of-life outcome (HRQoL) measure through SNOT-22 domains were published in the Laryngoscope.
    • 15 Jul 2019 Results assessing impact of dupilumab treatment on health-related quality of life published in the Allergy
    • 28 Nov 2018 Results assessing local effects of dupilumab on type 2 inflammatory biomarkers in nasal secretions and nasal polup tissues, published in the Allergy.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top